weight

GENESIS GV60 TAKES A CLASS WIN AT THE CARAVAN AND MOTORHOME CLUB TOWCAR OF THE YEAR AWARDS

London, United Kingdom, 23 September 2025:  Genesis has clinched the class winner for the GV60 Sport Plus in the Caravan…

3 weeks ago

Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants…

1 month ago

People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being

Results from a real-world survey suggest that semaglutide for weight management (Wegovy®) helped suppress food noise – unwanted and intrusive…

1 month ago

TrimIQ Weight Loss: Official launched in UK and Ireland With Green Tea Probiotic Complex

New York City, NY, Aug. 02, 2025 (GLOBE NEWSWIRE) -- TrimIQ UK, a pioneering health and wellness brand, proudly announces…

3 months ago

Pink Salt Trick Recipe to Weight Loss Trend 2025: An Analysis of Slumber Slim as a Science Informed Option

Albany, New York, July 26, 2025 (GLOBE NEWSWIRE) -- An internet-viral pink salt recipe has swept the TikTok platform purporting…

3 months ago

Fat Burner For Men Launched Over the Counter in USA PhenQ Medically Accredited Thermogenic Fat Burning Supplement for Men

Glasgow, UK, July 13, 2025 (GLOBE NEWSWIRE) -- Introduction: Why PhenQ Is Gaining Momentum in 2025 In a time when…

3 months ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

4 months ago

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

New York City, June 21, 2025 (GLOBE NEWSWIRE) -- Nixol, a plant-powered metabolic support supplement, is now available to individuals…

4 months ago

Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25%…

4 months ago

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

4 months ago